Intra-articular distribution and residence time of Hylan A and B: a study in the goat knee

Osteoarthritis and Cartilage

Volumn 14, Issue 12, 2006, Pages 1248-1257

  Jackson, D W ^a   Simon, T M ^a  

^a Southern California Center for Sports Medicine   (United States)

Author keywords

Hyaluronan; Hylan A; Hylan B; Osteoarthritis; Viscosupplementation

Indexed keywords

FLUORESCENT DYE; HYALURONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CONTROLLED STUDY; COVALENT BOND; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG RESPONSE; FEMALE; GOAT; HISTOLOGY; KNEE; LEUKOCYTE; MACROPHAGE; MEAN RESIDENCE TIME; MOLECULAR WEIGHT; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SYNOVIAL FLUID;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARTILAGE, ARTICULAR; GOATS; HYALURONIC ACID; LEUKOCYTE COUNT; MODELS, ANIMAL; MOLECULAR WEIGHT; PHAGOCYTOSIS; STIFLE; SYNOVIAL FLUID;

EID: 33751181466     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.05.015     Document Type: Article

References (60)

1. Chikanza I., and Fernandes L. Novel strategies for the treatment of osteoarthritis. Expert Opin Investig Drugs 9 (2000) 1499-1510
2. Westacott C.I., and Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction?. Semin Arthritis Rheum 25 (1996) 254-272
3. Moos V., Fickert S., Muller B., Weber U., and Sieper J. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 26 (1999) 870-879
4. Yuan G.-H., Hasuko-Hongo K., Kato T., and Nishioka K. Immunologic intervention in the pathogenesis of osteoarthritis. Arthritis Rheum 48 3 (2003) 602-611
5. Martel-Pelletier J., Alaaeddine N., and Pelletier J.-P. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 4 (1999) D694-D703
6. Van den Berg W.B. The role of cytokines and growth factors in cartilage destruction in osteoarthritis and rheumatoid arthritis. Z Rheumatol 58 (1999) 136-141
7. Melchiorri C., Meliconi R., Frizziero L., Silvestri T., Pulsatelli L., Mazzetti I., et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 41 (1998) 2165-2174
8. Tetlow L.C., Adlam D.J., and Woolley D.E. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 44 (2000) 585-594
9. Gouze J.N., Bordji K., Gulberti S., Terlain B., Netter P., Magdalou J., et al. Interleukin-1 down-regulates the expression of glucuronosyltransferase Ibeta, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta mediated effects in rat chondrocytes. Arthritis Rheum 44 (2001) 351-360
10. Mengshol J.A., Vincenti M.P., Coon C.I., Barchowsky A., and Brinckerhoff C.E. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 43 (2000) 801-811
11. American college of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medial management of osteoarthritis of the hip and knee. Arthritis Rheum 43 9 (2000) 1905-1915
12. Adams M.E., Atkinson M.H., Lussier A.J., Schuiz J.L., Siminovitch K.A., Wade J.P., et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 3 (1995) 213-225
13. Adams M.E. Viscosupplementation as an alternative to conventional treatment for the management of osteoarthritis of the knee. J Clin Rheumatol 5 (1999) S18-S23
14. Carrabba M., Paresce E., Angelini M., Re K.A., Torchiana E.E.M., and Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 15 (1995) 25-31
15. Dahlberg L., Lohmander L.S., and Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one-year, double-blind, placebo-controlled study. Arthritis Rheum 37 (1994) 521-528
16. Dougados M., Nguyen M., Listrat V., and Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial. Osteoarthritis Cartilage 1 (1993) 97-103
17. Henderson E.B., Smith E.C., Pegley F., and Blake D.R. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 53 (1994) 529-534
18. Jones A.C., Pattrick M., Doherty S., and Doherty M. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cartilage 3 (1995) 269-273
19. Kotz R., and Kolarz G. Intra-articular hyaluronic acid: duration of effect and results of repeated treatment cycles. Am J Orthop 28 Suppl 11 (1999) 5-7
20. Lohmander L.S., Dalen N., Englund G., Hamalainen M., Jensen E.M., Karlsson K., et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double-blind, placebo controlled, multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis 55 (1996) 424-431
21. Lussier A., Cividino A.A., McFarlane C.A., Olszynski W.P., Potashner W.J., and De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 23 (1996) 1579-1585
22. Puhl W., Bemau A., Greiling H., Kopcke W., Pforringer W., Steck K.J., et al. Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blinded study. Osteoarthritis Cartilage 1 (1993) 233-241
23. Scale D., Wobig M., and Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 55 (1994) 220-232
24. Scali J.J. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long-term study. Eur J Rheumatol Inflamm 15 (1995) 57-62
25. Wobig M., Beks P., Dickhut A., Maier R., and Vetter G. Open-label, multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 in primary osteoarthritis of the knee. J Clin Rheumatol 5 (1999) S24-S31
26. Wobig M., Dickhut A., Maier R., and Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 20 (1998) 410-423
27. Balazs E. The physical properties of synovial fluid and the specific role of hyaluronic acid. In: Helfet A.J. (Ed). Disorders of the Knee (1982), JB Lippincott, Philadelphia 61-74
28. ® PI (prescribing information). Memphis, TN: Smith and Nephew Inc., 2003.
29. ® PI (prescribing information). New York, NY: Sanofi-Synthelabo Inc., 2001.
30. ® PI (prescribing information). Bridgewater, NJ: Ortho Biotech Products, 2004.
31. Euflexxa™ (prescribing information). Suffern, NY: Ferring Pharmaceutical, 2006.
32. ® PI (prescribing information). Philadelphia, PA: Wyeth-Ayerst, 2004.
33. Jackson D.W., Evans N.A., and Thomas B.M. Accuracy of needle placement into the intra-articular space of the knee. J Bone Joint Surg 84A 9 (2002) 1522-1527
34. Isacke C.M., and Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol 34 (2002) 718-721
35. Takahashi K., Goomer R.S., Harwood F., Kubo T., Hirasawa Y., and Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 7 (1999) 182-190
36. Punzi L., Schiavon F., Cavasin F., Ramonda R., Gambari P.F., and Todesco S. The influence of intraarticular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clin Exp Rheumatol 7 (1989) 247-250
37. Goto M., Hanyu T., Yoshio T., Matsuno H., Shimizu M., Murata N., et al. Intra-articular injections of hyaluronate (SI6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 19 (2001) 377-383
38. Yasui T., Akatsuka M., Tobetto K., Hayaishi M., and Ando T. The effect of hyaluronan on interleukin-1 alpha induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 37 (1992) 155-156
39. Schiavinato A., Lini E., Guidolin D., Pezzoli G., Botti P., Martelli M., et al. Intra-articular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. II. Morphological findings. Clin Orthop 241 (1989) 286-299
40. Altman R.D., and Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 25 (1998) 2203-2212
41. Dixon A.S.J., Jacoby R.K., Berry H., and Hamilton E.B.D. Clinical trial of intraarticular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 11 (1988) 205-213
42. Bernardeau C., Bucki B., and Liote F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann Rheum Dis 60 (2001) 518-520
43. Goldberg V.M., and Coutts R.D. Pseudoseptic reactions to Hylan viscosupplementation - diagnosis and treatment. Clin Orthop Relat Res 419 (2004) 130-137
44. Puttick M.P., Wade J.R., Chalmers A., Connell D.G., and Rangno K.K. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 22 (1995) 1311-1314
45. ®. Clin Orthop 442 (2006) 187-194
46. Leopold S.S., Warme W.J., Pettis P.D., and Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (Synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am 84A 9 (2002) 1619-1623
47. American Veterinary Medical Association Panel on Euthanasia. 2000 Report. J Am Vet Med Assoc 218 5 (2001) 669-696
48. Balazs EA, Leschiner A, Larsen N, Band PI. Hylan preparation and method of recovery from animal tissues. Biomatrix Inc., US Patent 5,099,013, 1992.
49. Balazs E.A., and Leschiner A. Hyaluronan, its cross linked derivative - Hylan - and their medical applications. In: Inagaki H., and Phillips G.O. (Eds). Cellulosics Utilization Research and Rewards in Cellulosics (Proceedings of Nisshinbo International Conference on Cellulosics Utilization in the Near Future) (1989), Elsevier Applied Science, New York 223-241
50. Chen A.L., Panna D., Adler E.M., and DiCesare P.E. Granulomatous inflammation after Hylan GF20 viscosupplementation of the knee. A report of six cases. J Bone Joint Surg 84A 7 (2002) 1142-1147
51. Balazs E.A. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int 12 (2004) 278-289
52. Balazs E.A., and Denlinger J.L. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 39 (1993) 3-9
53. Moreland L.W. Review. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 5 (2003) 54-67
54. Goldring M.B. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 40 1 (1999) 1-11
55. Goldring M.B., and Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators prostaglandins and nitric oxide. Clin Orthop 427S (2004) s37-s46
56. Bernardeau C., Dernis-Labous E., Blanchard H., Lamarque D., and Breban M. Nitric oxide in rheumatology. Joint Bone Spine 68 6 (2001) 457-462
57. Karatay S., Kiziltunc A., Yildirim K., Karanfil R.C., and Senel K. Effects of different hyaluronic acid products on synovial fluid NO levels in knee osteoarthritis. Clin Rheumatol 24 5 (2005) 497-501 [Epub 2005 May 20]
58. Smith Jr. G.N., Myers S.L., Brandt K.D., and Mickler E.A. Effect of intraarticular hyaluronan injection in experimental canine osteoarthritis. Arthritis Rheum 41 6 (1998) 976-985
59. Julovi S.M., Yasuda T., Shimizu M., Hiramitsu T., and Nakamura T. Inhibition of interleukin-1-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum 50 2 (2004) 516-525
60. Ghosh P., and Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent?. Semin Arthritis Rheum 32 1 (2002) 10-37